Metys Pharmaceuticals is developing dimiracetam for the prevention of chemotherapy-induced painful peripheral neuropathy. In the US alone, in a single year, more than 400'000 patients suffer from the neuropathy caused by their life-saving cancer treatment. No drug has been approved to prevent or treat this condition. Dimiracetam is an orally active, small molecule with more than 200 patients' safety and tolerability data; dimiracetam is highly effective in preventing and treating chemotherapy-induced neuropathy in rodents. Metys Pharmaceuticals is preparing the first dedicated efficacy study of dimiracetam in this indication.
View Top Employees from Metys PharmaceuticalsWebsite | http://metys-pharma.ch |
Revenue | $1 million |
Employees | 2 (1 on RocketReach) |
Founded | 2013 |
Address | Leimenstrasse 57, Basel, Basel City 4051, CH |
Phone | +41 79 408 79 82 |
Fax | +41 61 568 40 70 |
Technologies |
JavaScript,
HTML,
Google Analytics
+7 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Medical, Drug development, Manufacturing, Health Care, Medical Device, Pharmaceutical |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Metys Pharmaceuticals employee's phone or email?
The Metys Pharmaceuticals annual revenue was $1 million in 2024.
Elisabet Lindberg is the Chief Medical Officer of Metys Pharmaceuticals.
1 people are employed at Metys Pharmaceuticals.
Metys Pharmaceuticals is based in Basel, Basel City.
The NAICS codes for Metys Pharmaceuticals are [32, 325, 3254, 32541].
The SIC codes for Metys Pharmaceuticals are [28, 283].